ACIU AC IMMUNE SA

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

Competitive EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent
EN
09/10/2020

Underlying

ACIUAC IMMUNE SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AC IMMUNE SA

 PRESS RELEASE
Free
ACIU AC IMMUNE SA

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immun...

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential antibody response in individuals with early Alzheimer’s diseaseACI-35.030, developed using AC Immune’s SupraAntigen® technology, generated rapid, potent polycl...

September 25, 2025 1 EN
Free Trial
ACIU AC IMMUNE SA

AC Immune Sa: 1 director

A director at AC Immune Sa sold 35,000 shares at 2.380USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

09/15/25 September 15, 2025 1 EN
 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extend...

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30%Increased emphasis on late-stage clinical development of active immunotherapy portfolio for Alzheimer’s and Parkinson’s diseases and progressing high value candidates enabling intracellular targetingNear term clinical milestones remain unchangedCash resources of CHF 127.1 million a...

September 4, 2025 1 EN
 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune Reports Second Quarter 2025 Financial Results and Provides a...

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical developmentACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025Third Alzheimer’s disease cohort (AD3) in the Phase 2...

August 5, 2025 1 EN
 PRESS RELEASE
Free
ACIU AC IMMUNE SA

AC Immune Reports First Quarter 2025 Financial Results and Provides a ...

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive immunogenicity and good safety in interim results for wholly owned anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in Phase 2 trial in Parkinson’s disease (PD)Additional ACI-7104.056 Phase 2 interim results (pharmacodynamics and biomarkers) expected in Q2 2025Presentations at Inter...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch